Survival With Olanzapine in Patients With Locally Advanced or Metastatic Upper Gastrointestinal and Lung Cancer

This study aims to assess the impact of adding olanzapine to nutritional advice and standard anti-tumor therapy on the survival and safety of patients with locally advanced, unresectable or metastatic gastric cancer, esophageal cancer, hepato-pancreaticobiliary cancer, and lung cancer. Researchers seek to determine whether olanzapine can improve progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) in advanced cancer patients who received standard anti-tumor therapy, and investigate the relationship between olanzapine-induced weight changes and patient survi

Trial Details

NCT ID
NCT06338683
Phase
PHASE3
Sponsor
Qinghai Red Cross Hospital
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Olanzapine 2.5 MG
  • Standard anti-tumor treatment
  • Nutritional advice
Locations (sample)
  • Xining, Qinghai, China|36.62554,101.75739

Key Eligibility Criteria

  • Aged 18 years or older;
  • Eastern Cooperative Oncology Group performance status of 0-3;
  • Stage III or IV inoperable or metastatic gastric cancer, esophageal cancer, hepato-pancreaticobiliary cancer and lung cancer confirmed by histology…
  • Subjected to palliative systemic chemotherapy, regardless of first-line or second-line treatment;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →